Closing the Diagnostic Gap: Utilizing pTau217 for Scalable Alzheimer’s Disease Diagnosis

Sunday, July 12: 12:30-1:45 p.m.
Crowne Plaza London Docklands (Docklands Suite)

This symposium explores the transformative role of pTau217 — a high-performance blood biomarker — in revolutionizing how we identify Alzheimer’s disease. As clinical practice shifts away from invasive spinal taps and costly PET scans, this session examines how scalable blood tests are bridging the "diagnostic gap," enabling earlier detection and expanding global access to disease modifying therapies.

The session will feature two speakers who will provide their expertise and insights on the clinical performance of pTau217 and its role in the clinical workflows.

Speakers:

• Alicia Algeciras Schimnich (Mayo Clinic, United States)
• Nicholas Ashton (Banner Health, United States)
• Craig Ritchie (Scottish Brain Sciences, United Kingdom)

Note: The content of these sessions is owned by: Roche Diagnostics

Sponsored by: Roche

Improving Real World Representation in Alzheimer’s Disease Clinical Research and Treatment

Monday, July 13: 12:30-1:45 p.m.
Crowne Plaza London Docklands (Docklands Suite)

This scientific symposium will review progress in plasma biomarkers as scalable diagnostic foundations, highlight persistent under-representation in patient demographics, and outline actionable steps to strengthen scientific understanding and promote widespread adoption.

Ensuring that emerging Alzheimer’s disease (AD) diagnostic strategies reflect real-world patient diversity is essential for accurate and equitable care. Today’s clinical research cohorts are largely composed of educated, health-aware individuals with limited demographic and pathological variability, constraining the generalizability of plasma-based tests. These gaps can lead to variable test performance across populations and care settings. Strengthening representation requires expanding awareness of blood‑based tools, improving clinician and community education, and generating real‑world evidence from heterogeneous groups.

Jeremiah Hinson, NDD CSO, will open the symposium by introducing recent advances in plasma-based Alzheimer’s disease biomarkers, highlighting persistent gaps in patient representation and outlining actionable paths toward scientifically robust and equitable real-world adoption. Panelists will then present their research approaches to addressing these gaps, followed by audience Q&A.

Sponsored by: Danaher and Beckman Coulter Diagnostics

From Evidence to Life: A Clinical and Human Perspective in Early Alzheimer’s Disease

Monday, July 13: 6-7:30 p.m.
Crowne Plaza London Docklands (Docklands Suite)

Translating robust clinical trial evidence into confident and effective real-world practice demands a different kind of conversation: one grounded not only in data, but in clinical experience, patient stories, and honest dialogue about what works, and what challenges remain. This symposium starts by giving a voice to people living with Alzheimer’s disease and their personal experiences. Building on these perspectives, leading experts in Alzheimer’s disease will discuss how emerging therapies translate into real-world practice — from early diagnosis and patient selection to clinical efficacy and safety — and the implications for patients across the care journey.

This promotional event has been developed, organized and funded by Eli Lilly and Company. Lilly products will be discussed at this event. Prescribing information and adverse event reporting information will be available at the meeting.

© 2026 Eli Lilly and Company. All rights reserved. Lilly is a registered trademark of Eli Lilly and Company.

CMAT-37475. June 2026.

Sponsored by: Eli Lilly and Company

Note: The content of this symposium may be promotional in nature and intended only for Healthcare Professionals.

Early Intervention in Alzheimer’s Disease: Building the Evidence from Pathology to Practice

Tuesday, July 14: 12:30-1:45 p.m.
Crowne Plaza London Docklands (Docklands Suite)

Understanding early intervention in Alzheimer’s disease (AD) requires looking beyond a single data source. Join the expert faculty as they discuss why prompt diagnosis, followed by early intervention and long-term management of MCI and mild dementia in AD is important for clinical practice.

The session will review real-world evidence alongside clinical trial data to show how to identify appropriate patients. You’ll also learn how to apply these insights in routine care to support informed clinical conversations.

Join the discussion through live audience polling and a dedicated Q&A session with faculty. This is an Eisai-organized and funded promotional symposium for healthcare professionals and will discuss Eisai medicines.

EMEA-LECA-26-00121 ⏐ June 2026

Sponsored by: Eisai and Biogen

Note: The content of this symposium may be promotional in nature and intended only for Healthcare Professionals.

Emerging Data, Collective Impact: A Global Consortium Approach to Alzheimer’s Research

Wednesday, July 15: 12:30-1:45 p.m.
Crowne Plaza London Docklands (Docklands Suite)

Global efforts in Alzheimer’s disease and related dementias are converging through collaborative consortia integrating diverse datasets, technologies, and expertise. Initiatives such as the Sex | Gender in Neurodegeneration Consortium (S|GN), Global Neurodegeneration Proteomics Consortium (GNPC), and NULISA NeuroData Commons are advancing “emerging data” resources: harmonized, cross-cohort datasets enabling deeper understanding of disease heterogeneity, biomarker discovery, and translational insights.

This symposium will showcase how consortium-driven infrastructure and partnerships accelerate early insights and expand access to high-value datasets: highlighting shared approaches, early scientific signals, and opportunities for broader participation to drive open, global discovery.

Sponsored by: Alzheimer's Disease Data Initiative